MedTrace Logo

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

NCT02237235 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-22

Study results available
· View outcomes & findings →

Summary

The goals of this study are to study MMFS-202-302 in a double blind, randomized, placebo-controlled 9-week study of its effect on ameliorating cognitive deficits in 60 patients with schizophrenia or schizoaffective disorder with stable levels of positive symptoms. Secondary end points will include changes in positive and negative symptoms. One dose of MMFS-202-302 will be studied and compared with placebo as adjunctive treatment to atypical antipsychotic drug treatment.

Conditions

Interventions

DRUG

MMFS-202-302

Active ingredient: L-Threonic acid Magnesium salt. 1 g (2 pills) by mouth once daily in the evening for 9 weeks Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt 1 g (2 pills) by mouth once daily in the morning for 9 weeks

DRUG

Placebo

Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.

Sponsors & Collaborators

  • Neurocentria, Inc.

    collaborator INDUSTRY

  • Brain & Behavior Research Foundation

    collaborator OTHER

  • Northwestern University

    lead OTHER

Principal Investigators

  • Herbert Y Meltzer, MD · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02237235 on ClinicalTrials.gov